dismiss

Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

starstarstarstarstar (2)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Dennis Durmis MITA names chair of board of directors

Researchers find new PET tracer that better detects melanoma than 18F-FDG 18F-P3BZA could become the new gold standard

RadioMedix scores $2 million contract for Targeted Alpha-emitter therapy Treatment for neuroendocrine tumors

FDA clears United Imaging's total-body PET scanner Creating 3D images of entire human body in 15-30 seconds

FDA clears MIM SurePlan molecular radiotherapy software Can measure the absorbed dose from MRT for individual patients

Rob Beanlands ASNC names president for 2019

Congress to evaluate bill to reclassify
radiopharmaceuticals in Medicare
outpatient-based settings

New House bill calls for change in CMS definition of radiopharmaceuticals

by John R. Fischer , Staff Reporter
A new bill is calling for CMS to recognize diagnostic radiopharmaceuticals as drugs under the Medicare Hospital Outpatient Prospective Payment System, to spare hospitals the financial burdens associated with their current classification as supplies.

Introduced late last month by congressmen George Holding (R.-NC) and Seth Moulton (D.-MA) in the U.S. House of Representatives, the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 seeks to change the status of radiopharmaceuticals so that they may be paid for separately in Medicare hospital outpatient settings rather than as bundled payments.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510



“Supplies are considered ancillary to a procedure in the Medicare hospital outpatient setting, and therefore payment is packaged into the payment for the scan,” Patrick Hope, executive director of the Medical Imaging & Technology Alliance (MITA), told HCB News. “The current CMS averaging system packages lower-volume, higher-cost diagnostic radiopharmaceuticals with other higher-volume, lower-cost drugs. In some instances, the cost of the diagnostic radiopharmaceutical exceeds the entire packaged amount of reimbursement, creating the potential for hospitals to lose money every time they perform the procedure.”

As a result of these difficulties, many small providers are hesitant to perform certain exams, such as an Octreoscan procedure to visualize hormone-producing tumors in the nervous and endocrine systems. The cost of this procedure ranges from $1,200 to 1,400 with reimbursement nowhere near that amount, causing patients in need of it to seek help from bigger, far away facilities.

In addition, including radiopharmaceuticals as a bundled payment also deters research and innovation, with companies less inclined to spend money on development for such compounds due to providers unwilling to purchase them.

Hope says the passage of H.R. 6948 would open up access for patients to necessary diagnostic exams for a variety of diseases, including cancer, neurologic, and cardiac conditions, improving diagnostic accuracy and enabling physicians to develop treatments that avoid unnecessary procedures.

He also points out that doing so would eliminate inconsistencies in CMS’ definition of diagnostic radiopharmaceuticals, which depends on the site of care, with freestanding, non-hospital based imaging centers recognizing them as drugs and paid for as such by CMS, in contrast to hospital-based outpatient settings.

“These drugs go through the rigor of the FDA approval process and should therefore be considered the same as other drugs,” he said, adding that the FDA regulates radiopharmaceuticals as drugs. “Paying separately at a $500 drug threshold will provide more appropriate reimbursement, ensure patients have access to vital diagnostic tests, and allow for continued innovation in molecular imaging.”

Whether or not the bill will pass in the coming months is “hard to say”, according to Hope, due to the end of the year approaching and “uncertainty” over the outcome of the midterm elections.

MITA, however, plans to work with other stakeholders to ensure the bill does become law.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED